78,249 Shares in 10x Genomics $TXG Purchased by Counterpoint Mutual Funds LLC

Key Points

• Counterpoint Mutual Funds LLC has acquired 78,249 shares of 10x Genomics, with a total value of approximately $906,000, representing a 0.06% ownership of the company.
• Several large investors, including Amundi and UBS AM, have significantly increased their stakes in 10x Genomics during the first quarter, reflecting strong institutional interest.
• Analysts currently have a consensus rating of "Hold" for 10x Genomics, with a consensus price target of $13.65, indicating mixed views on the stock's future performance.

Counterpoint Mutual Funds LLC bought a new position in shares of 10x Genomics (NASDAQ:TXG - Free Report) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 78,249 shares of the company's stock, valued at approximately $906,000. Counterpoint Mutual Funds LLC owned 0.06% of 10x Genomics at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. GAMMA Investing LLC lifted its position in 10x Genomics by 81.8% during the first quarter. GAMMA Investing LLC now owns 3,586 shares of the company's stock worth $31,000 after buying an additional 1,614 shares during the period. Amundi increased its stake in 10x Genomics by 16,013.7% during the first quarter. Amundi now owns 320,340 shares of the company's stock worth $2,553,000 after acquiring an additional 318,352 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in 10x Genomics by 235.6% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,103,768 shares of the company's stock worth $62,016,000 after acquiring an additional 4,987,195 shares during the last quarter. Goldman Sachs Group Inc. increased its stake in 10x Genomics by 163.5% during the first quarter. Goldman Sachs Group Inc. now owns 645,366 shares of the company's stock worth $5,634,000 after acquiring an additional 400,430 shares during the last quarter. Finally, Deutsche Bank AG increased its stake in 10x Genomics by 35.3% during the fourth quarter. Deutsche Bank AG now owns 10,190 shares of the company's stock worth $146,000 after acquiring an additional 2,657 shares during the last quarter. 84.68% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the company. Canaccord Genuity Group set a $16.00 price target on 10x Genomics in a research note on Monday, August 11th. Wall Street Zen lowered 10x Genomics from a "buy" rating to a "hold" rating in a research note on Saturday, September 13th. Deutsche Bank Aktiengesellschaft set a $14.00 target price on 10x Genomics and gave the company a "hold" rating in a research note on Friday, August 8th. Weiss Ratings reiterated a "sell (e+)" rating on shares of 10x Genomics in a research note on Saturday, September 13th. Finally, Barclays reiterated an "overweight" rating and issued a $15.00 target price (up previously from $13.00) on shares of 10x Genomics in a research note on Friday, August 8th. Six analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus price target of $13.65.

Insider Buying and Selling

In related news, insider Benjamin J. Hindson sold 7,486 shares of the firm's stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $13.79, for a total value of $103,231.94. Following the sale, the insider owned 440,888 shares of the company's stock, valued at approximately $6,079,845.52. This trade represents a 1.67% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Adam Taich sold 22,315 shares of the firm's stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $13.79, for a total value of $307,723.85. Following the completion of the sale, the chief financial officer directly owned 309,273 shares in the company, valued at approximately $4,264,874.67. This trade represents a 6.73% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 39,149 shares of company stock valued at $539,865. Insiders own 10.03% of the company's stock.

10x Genomics Price Performance

NASDAQ:TXG opened at $13.04 on Tuesday. The business's 50 day moving average is $13.30 and its two-hundred day moving average is $10.90. 10x Genomics has a 52 week low of $6.78 and a 52 week high of $23.16. The company has a market cap of $1.62 billion, a PE ratio of -18.63 and a beta of 2.00.

10x Genomics (NASDAQ:TXG - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported $0.28 EPS for the quarter, topping analysts' consensus estimates of ($0.35) by $0.63. The company had revenue of $172.91 million for the quarter, compared to the consensus estimate of $139.36 million. 10x Genomics had a negative return on equity of 12.88% and a negative net margin of 13.13%.10x Genomics's quarterly revenue was up 12.9% compared to the same quarter last year. During the same quarter last year, the business posted ($0.32) EPS. 10x Genomics has set its Q3 2025 guidance at EPS. As a group, sell-side analysts expect that 10x Genomics will post -1.43 EPS for the current fiscal year.

10x Genomics Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.

Want to see what other hedge funds are holding TXG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for 10x Genomics (NASDAQ:TXG - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.